PresentationtointernationalporphyriapatientgroupMelbourne,AustraliaandLeatherhead,UK,February8,2016

ClinuvelPharmaceuticalsLtd(ASX:CUV;XETRA‐DAX:UR9;ADR:CLVLY)presentedtoaninternationalporphyriapatientmeeting,heldinRotterdam,theNetherlands,onFebruary6,2016.Thepresentationandspeakingnotesareappendedtothisannouncement.‐End‐AboutClinuvelPharmaceuticalsLimitedClinuvelPharmaceuticalsLtd(ASX:CUV;XETRA‐DAX:UR9;ADR:CLVLY)isaglobalbiopharmaceuticalcompanyfocused on developing drugs for the treatment of a range of severe disorders. With its unique expertise inunderstandingtheinteractionoflightandhumanskin,thecompanyhasidentifiedpatientpopulationswithaclinicalneedforphotoprotectionandforrepigmentation.Theworldwideprevalenceofthesepatientgroupsrangefrom5,000to45million.Clinuvel’sleadcompound,SCENESSE®(afamelanotide16mg),wasapprovedbytheEuropeanCommissionin2014forthepreventionofphototoxicityinadultpatientswitherythropoieticprotoporphyria(EPP).HeadquarteredinMelbourne,Australia,ClinuvelhasoperationsinEurope,Switzerland,theUSandSingapore.Formoreinformationgotohttp://www.clinuvel.com.SCENESSE®isaregisteredtrademarkofClinuvelPharmaceuticalsLtd.InvestorenquiriesInvestorRelations@clinuvel.com

Forward‐LookingStatementsThis release to theAustralianSecuritiesExchangeand topressmaycontain forward‐lookingstatements, includingstatements regardingfutureresults,performanceorachievements.Thesestatementsinvolveknownandunknownrisks,uncertaintiesandotherfactorswhichmaycauseClinuvel’sactualresults,performanceorachievementstobemateriallydifferentfromanyfutureresults,performancesorachievementsexpressedorimpliedbytheforward‐lookingstatements.Thesestatementsreflectourcurrentviewswithrespecttofutureeventsandarebasedonassumptionsandsubjecttorisksanduncertainties.Giventheseuncertainties,youshouldnotplaceunduerelianceontheseforward‐lookingstatements.Someofthefactorsthatcouldaffecttheforward‐lookingstatementscontainedhereininclude:thattheFDAmayrequireadditionalstudiesbeyondthestudiesplannedforproductcandidatesormaynotprovideregulatoryclearances,includingforSCENESSE®;thattheFDAmaynotprovideregulatoryapprovalforanyuseofSCENESSE®orthattheapprovalmaybelimited;thatClinuvelmayneverfileanNDAforSCENESSE®regulatoryapprovalintheUS;thattheCompanymaynotbeabletoaccessadequatecapitaltoadvanceitsvitiligoprograms;thattheCompanymaynotbeabletoretainitscurrentpharmaceuticalandbiotechnologykeypersonnelandknowhowforfurtherdevelopmentofitsproductcandidatesormaynotreachfavourableagreementswithpotentialpricingandreimbursementagenciesinEuropeandtheUS.Level5,160QueenStreet T+61396604900 www.clinuvel.comMelbourne,Victoria3000 F+61396604999Australia

For

per

sona

l use

onl

y

InlinewithEuropeanGuidelines onMedicalAdvertisingandUKAdvertisingStandardsforMedicinalProducts,ClinuvelwillnotdiscusstheprofileoftheproductSCENESSE®(afamelanotide16mg)duringthismeeting.Theproductisapprovedtopreventphototoxicityinadulterythropoieticprotoporphyria(EPP)patients.InformationontheproductcanbefoundonClinuvel’swebsiteatwww.Clinuvel.com.Today’sinvitationisappreciatedandisaheadof thelaunchofSCENESSE®inEurope.ThedistributionofSCENESSE®asafirst‐in‐classproduct.Thereareanumberofchallengesinyearstocome,oneoftheseistheperceptionthattheproductcouldbeusedoff‐label;Clinuvelwilldoitsutmosttoavoidthis.Regulatoryconcernscentrearoundthisaspect.

1

For

per

sona

l use

onl

y

Thepossibleforwardlookingstatementsinthisdiscussionare notaimedatinvitingorsolicitinginterestinthecompany.

2

For

per

sona

l use

onl

y

Today’sdiscussionpointsarerelevant tophysicians,expertsinthetreatmentofthedisease,andEPPpatientsandtheirfamilies.

3

For

per

sona

l use

onl

y

Thefirstdiscussionpoint isaimedatcharacterisationofthedisorder.

4

For

per

sona

l use

onl

y

Thestigmaspatientshavereported toourteamsovertheyearsarefoundinanabundanceofletters,emailsandfromphoneconversations(left).Thelabellingofthediseasebybystanders,‘outsiders’,differsfromthedescriptionpatientsseemtogivethemselves(right).

5

For

per

sona

l use

onl

y

In2005therewere anumberofkeyquestionsindevelopingadrugforEPP,howeverthehypothesisofSCENESSE®wasansweredafterthefirststudyin2006.Theresponsesfrompatientsandphysicianshasbeenstrongerthanexpected.

6

For

per

sona

l use

onl

y

In generalonecannotfullyunderstandthesufferingofapatientuntiloneexperiencestheordeal,symptomsanddiseaseher/himself.Thiswillalwaysbethechasmbetweendrugcompaniesandpatients.Adiscussiononhuman’sdiscriminatorysensesandespeciallyEPP‐patients’abilitytodiscern“visiblelight”isled.

7

For

per

sona

l use

onl

y

OvertheyearseightcharacteristicsofEPPhavebeenidentifiedbyourteamsandexperts,andallofthemmakethediseasecomplextoevaluate.Inaddition,astherearenoappropriatescientifictoolstomeasurethecharacteristicsymptoms,theClinuvelprogramledtooptimumsynthesisofamolecule,formulation,environmentandvariableclinicalprogram.

8

For

per

sona

l use

onl

y

Aspartoftheregulatorydiscussionsandfilings,thisdiagramwas developedandisdiscussedtoday.EPPpatientsareself‐limitingtheirabilitytoexposeduetothecharacteristicsofthedisorder.AnumberofbehaviouralcomponentsmakeEPPdifferentfromotherlightinduceddisorders,rarediseasesororphandiseases.

9

For

per

sona

l use

onl

y

Thenexttopicisthepaediatric development.

10

For

per

sona

l use

onl

y

Theestimatedtime ofdevelopmentisapproximately36months,costingmillionsofEUROsincludingproductdevelopment,clinicaltrials,regulatoryfilings,followupofpatients.Theregulatoryviewswilllargelydeterminefurthertimelines.ThesuccessfulcompletionofthedevelopmentofthepaediatricproductdependsoncontinuedsafetyofSCENESSE®reportedinadultEPPpatients,capturedviatheEuropeanEPPDiseaseRegistry(EEDR).

11

For

per

sona

l use

onl

y

Thethirdtopicisriskmanagement.

12

For

per

sona

l use

onl

y

Themaineightpointsarepartoftheprotocolised treatmentofEPPinEurope,alsoexpectedinotherpartsoftheworld.TheoverallcommitmentforanydeveloperofnoveldrugsistoemphasisePHARMACOVIGILANCE,theabilitytobeextravigilantforitspatientslongterm;Clinuvelundertakesthis.

13

For

per

sona

l use

onl

y

Clinuvel’sinitialroll‐outfocusisonthose countrieswithknownpatientpopulations.Thecompany’sdistributioncentreisLeatherhead,UK.

14

For

per

sona

l use

onl

y

WithintheEUeachcountryisassessingtheproductonanumberofcriteria,including: benefit,costtosociety,numberofpatientsexpected and riskofoff‐labeluse.

15

For

per

sona

l use

onl

y

UnderEuropeanmarketingauthorisation,Clinuvelis establishingandmaintaininganEPP‐specificDiseaseRegistry(EEDR).Theownershipofthemedicaldatawillremainwiththeindividualpatientsandresideineachmedicalcentre,howeverthepseudonymisedmedicaldatarelatedtoEPPwillbemade availabletothe EEDR,andClinuvelwill haveunrestrictedaccesstothesedataforanalyticalpurposestofulfilregulatoryrequirementsoflongtermfollowupofpatients.

16

For

per

sona

l use

onl

y

SettimelineshavebeenestablishedbyEMAforClinuvelto reportdatafromitsEuropeanprogram.Thetimelinesgivenhereprovideasample12monthreportingrequirement.

17

For

per

sona

l use

onl

y

Thedataflowestablished forpharmacovigilanceiscomplex.Ateachpointoftheseprocesses,thereare controlsinplaceandallthesecontrolsformpartofapharmacovigilancemanagementsystem.Each‘station’onthechartrequiresindependentauditingofprocesses,propermanagementandadequateprotectionofmedicaldata.Anumberofadvisorybodies,governanceboards(GovernanceBoard‐ GOB;DataSafetyMonitoringBoard‐ DSMB;MelanocyteSignallingExpertGroup‐ MSEG)andthirdpartyauditorsworkaroundtheclockaspartofpharmacovigilancewithSCENESSE®.Thiscomplexsystemiscompulsoryandaimstoprotectsafetyofpatientslongterm.

18

For

per

sona

l use

onl

y

Asummaryis provided.

19

For

per

sona

l use

onl

y

20

For

per

sona

l use

onl

y

21

For

per

sona

l use

onl

y

Intherenaissanceartistsweretryingtocapturelightinshadowson canvas.ClinuvelhopestoprovidelightforEPPpatientswhohaveledalifeonthefringeandindarkness.

22

For

per

sona

l use

onl

y

Clinuvel hasdevotedmorethanadecadetoonedruginonedisorder,theresponseofpatientsandphysicianshasmadethisjourneyworthwhile.

23

For

per

sona

l use

onl

y

Thankyou fortheinvitation.

24

For

per

sona

l use

onl

y